TRANSGENE (TRGNY) and Tasly Pharmaceutical JV Starts Operations With Four Transgene Molecules  
7/27/2012 12:24:12 PM

by Richard Daverman, PhD

July 27, 2012 -- The JV established by France’s Transgene and Tasly Pharma of China announced that Transgene is contributing China rights to four biotech immunotherapeutic candidates to the JV. The JV will be capitalized with $3.2 million from Transgene and $6.6 million from Tasly. The value of Transgene’s drug IP evens its investment in the 50:50 partnership with Tasly’s. Transgene develops immunotherapeutic products aimed at cancer and infectious diseases. More details....

Stock Symbols: (Euronext: TNG) (SHA: 600535)